91 related articles for article (PubMed ID: 18779044)
21. HSV therapy and HIV-1 reduction.
Eisenhut M
N Engl J Med; 2007 May; 356(22):2323-4; author reply 2324. PubMed ID: 17542070
[No Abstract] [Full Text] [Related]
22. Acyclovir. A review of its pharmacodynamic properties and therapeutic efficacy.
Richards DM; Carmine AA; Brogden RN; Heel RC; Speight TM; Avery GS
Drugs; 1983 Nov; 26(5):378-438. PubMed ID: 6315332
[TBL] [Abstract][Full Text] [Related]
23. [Acyclovir-resistant Herpes simplex viruses in HIV-infected patients].
Baumann R; Wunderli W; Riess C; Vogt M
Schweiz Med Wochenschr; 1993 Dec; 123(51-52):2394-400. PubMed ID: 8290931
[No Abstract] [Full Text] [Related]
24. Long-term follow-up of HIV-infected patients once diagnosed with acyclovir-resistant herpes simplex virus infection.
Seang S; Boutolleau D; Burrel S; Regnier S; Epelboin L; Voujon D; Valantin MA; Katlama C; Agut H; Caumes E
Int J STD AIDS; 2014 Aug; 25(9):676-82. PubMed ID: 24535691
[TBL] [Abstract][Full Text] [Related]
25. Obstructive endo-bronchial pseudotumour due to herpes simplex type 2 infection in an HIV-infected man.
Plowman GM; Watson MW; D'Souza H; Thomas MG
Int J STD AIDS; 2009 Oct; 20(10):737-8. PubMed ID: 19815922
[TBL] [Abstract][Full Text] [Related]
26. Acyclovir: a new use for an old drug.
Vanpouille C; Lisco A; Margolis L
Curr Opin Infect Dis; 2009 Dec; 22(6):583-7. PubMed ID: 19726982
[TBL] [Abstract][Full Text] [Related]
27. Synthesis and antiviral activity of novel acyclic nucleosides: discovery of a cyclopropyl nucleoside with potent inhibitory activity against herpesviruses.
Sekiyama T; Hatsuya S; Tanaka Y; Uchiyama M; Ono N; Iwayama S; Oikawa M; Suzuki K; Okunishi M; Tsuji T
J Med Chem; 1998 Apr; 41(8):1284-98. PubMed ID: 9548818
[TBL] [Abstract][Full Text] [Related]
28. Transient Increase in Herpes Simplex Virus Type 2 (HSV-2)-Associated Genital Ulcers Following Initiation of Antiretroviral Therapy in HIV/HSV-2-Coinfected Individuals.
Fife KH; Mugwanya K; Thomas KK; Baeten JM; Celum C; Bukusi E; de Bruyn G; Mujugira A; Vwalika B; Wald A; Lingappa JR;
J Infect Dis; 2016 May; 213(10):1573-8. PubMed ID: 26704611
[TBL] [Abstract][Full Text] [Related]
29. Treating HIV infection with drugs for HSV-2 infection?
Buvé A; Lynen L
Lancet; 2010 Mar; 375(9717):782-4. PubMed ID: 20153889
[No Abstract] [Full Text] [Related]
30. Acyclovir-resistant, pathogenic herpesviruses.
Coen DM
Trends Microbiol; 1994 Dec; 2(12):481-5. PubMed ID: 7889324
[TBL] [Abstract][Full Text] [Related]
31. Herpes simplex virus (HSV)-suppressive therapy decreases plasma and genital HIV-1 levels in HSV-2/HIV-1 coinfected women: a randomized, placebo-controlled, cross-over trial.
Baeten JM; Strick LB; Lucchetti A; Whittington WL; Sanchez J; Coombs RW; Magaret A; Wald A; Corey L; Celum C
J Infect Dis; 2008 Dec; 198(12):1804-8. PubMed ID: 18928378
[TBL] [Abstract][Full Text] [Related]
32. An unusual vulval lesion in an HIV-infected woman.
Boothby M; Radcliffe K
Int J STD AIDS; 2007 Mar; 18(3):218-9. PubMed ID: 17362560
[TBL] [Abstract][Full Text] [Related]
33. Cytopathic effect inhibition assay for determining the in-vitro susceptibility of herpes simplex virus to antiviral agents.
Cotarelo M; Catalán P; Sánchez-Carrillo C; Menasalvas A; Cercenado E; Tenorio A; Bouza E
J Antimicrob Chemother; 1999 Nov; 44(5):705-8. PubMed ID: 10552991
[TBL] [Abstract][Full Text] [Related]
34. Herpes treatment may limit HIV transmission and progression.
Wilkinson E
Lancet Infect Dis; 2007 Apr; 7(4):249. PubMed ID: 17419138
[No Abstract] [Full Text] [Related]
35. Phenotypic and genotypic characterization of acyclovir-resistant herpes simplex viruses from immunocompromised patients.
Gaudreau A; Hill E; Balfour HH; Erice A; Boivin G
J Infect Dis; 1998 Aug; 178(2):297-303. PubMed ID: 9697707
[TBL] [Abstract][Full Text] [Related]
36. Severe acyclovir-resistant herpes simplex virus 1 infection following cord blood transplantation.
Shigemura T; Nakazawa Y; Yoshikawa T; Fujii H; Yamada S; Saijo M; Okuyama R
Int J Hematol; 2018 Sep; 108(3):237-238. PubMed ID: 29923124
[No Abstract] [Full Text] [Related]
37. Herpes Simplex Virus Suppressive Therapy in Herpes Simplex Virus-2/Human Immunodeficiency Virus-1 Coinfected Women Is Associated With Reduced Systemic CXCL10 But Not Genital Cytokines.
Andersen-Nissen E; Chang JT; Thomas KK; Adams D; Celum C; Sanchez J; Coombs RW; McElrath MJ; Baeten JM
Sex Transm Dis; 2016 Dec; 43(12):761-764. PubMed ID: 27832025
[TBL] [Abstract][Full Text] [Related]
38. Uncontrolled herpes simplex virus-2 as a cofactor in HIV transmission.
Gisselquist D; Potterat JJ
J Acquir Immune Defic Syndr; 2003 May; 33(1):119-20. PubMed ID: 12792367
[No Abstract] [Full Text] [Related]
39. Successful treatment of progressive mucocutaneous infection due to acyclovir- and foscarnet-resistant herpes simplex virus with (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine (HPMPC).
Snoeck R; Andrei G; Gérard M; Silverman A; Hedderman A; Balzarini J; Sadzot-Delvaux C; Tricot G; Clumeck N; De Clercq E
Clin Infect Dis; 1994 Apr; 18(4):570-8. PubMed ID: 8038312
[TBL] [Abstract][Full Text] [Related]
40. The Anti-Human Immunodeficiency Virus Drug Tenofovir, a Reverse Transcriptase Inhibitor, Also Targets the Herpes Simplex Virus DNA Polymerase.
Andrei G; Gillemot S; Topalis D; Snoeck R
J Infect Dis; 2018 Feb; 217(5):790-801. PubMed ID: 29186456
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
